$QURE

Kapusta Matthew C sold $952K of QURE

Kapusta Matthew C (CEO, Managing Director) sold 21,082 shares of uniQure N.V. (QURE) at an average of $45.16 ($44.43–$45.89, $0.95M total) across 3 trades on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kapusta Matthew C
Published Jul 7, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 7, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The newest disclosed fact is the CEO’s open-market sale amount, share count, and the fact it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Provides a fresh datapoint on insider activity, but with 10b5-1 context it is unlikely to drive a major repricing alone.

03

What to watch

Traders may over-weight insider sales; the key is whether there are concurrent fundamental catalysts (earnings, trial updates) not present in this filing.

Relevance 4/10Novelty 4/10Timing: Filed after-hours on 2026-07-07; reflects sales executed on 2026-07-02.

Background

The article is a SEC Form 4 insider transaction report for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

uniQure CEO Matthew C Kapusta sold $952,051 of QURE shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be small and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 open-market sale with a stated 10b5-1 plan, which typically reduces signaling value versus discretionary selling.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may be largely mechanical and not a bearish signal.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider transaction disclosure.

  • Kapusta Matthew C

    CEO, Managing Director; reported open-market sale of QURE shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.